
Opinion|Videos|April 22, 2024
Treatment Paradigm for Metastatic Upper GI Cancers
Dr Klempner and the Oncology Brothers discuss the treatment paradigm for patients with metastatic upper GI cancers.
Advertisement
Advertisement
Related to this article

“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.

ADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.

Neoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.

Rezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.

Anne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.

The FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.

Variation in the mitochondrial genome carries prognostic information about graft-versus-host disease that current clinical risk scores do not capture.
Advertisement
Advertisement
Trending on CancerNetwork
1
Rezatapopt Shows Durable Responses in TP53 Y220C-Mutated PROC
2
Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer
3
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
4
FDA Grants RMAT Designation to iSCIB1+ in Advanced Melanoma
5

